<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-140421" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Bimatoprost Ophthalmic Solution</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Huang</surname>
            <given-names>Andy S.</given-names>
          </name>
          <aff>New York Eye and Ear Infirmary of Mount Sinai</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zeppieri</surname>
            <given-names>Marco</given-names>
          </name>
          <aff>University Hospital of Udine, Italy</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Meyer</surname>
            <given-names>Jay J.</given-names>
          </name>
          <aff>University of Auckland</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andy Huang declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Marco Zeppieri declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jay Meyer declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-140421.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Bimatoprost ophthalmic solution is a medication that addresses medical and cosmetic concerns. This activity discusses&#x000a0;this eye drop's chemical intricacies, pharmacodynamics, and pharmacokinetics, shedding light on its therapeutic role in reducing intraocular pressure (IOP) among patients with primary open-angle glaucoma (POAG) and ocular hypertension. This prostaglandin (PG) F2 alpha analog exerts its influence by activating bimatoprost-sensitive receptors scattered across various&#x000a0;ocular structures. Understanding the mechanisms of action is paramount, as these receptors play a pivotal role in enhancing aqueous humor outflow, ultimately mitigating intraocular pressure.</p>
        <p>This&#x000a0;activity extends beyond the biochemical aspects, comprehensively exploring the drug's indications, administration guidelines, potential adverse effects, and contraindications. Furthermore, it underscores the collaborative efforts of an interprofessional team in optimizing the therapeutic efficacy of bimatoprost ophthalmic solution. Beyond its medical utility, the activity also discusses the cosmetic application of bimatoprost in addressing hypotrichosis, adding a layer to its clinical significance. Participants gain valuable insights into the holistic management of patients using this multifunctional medication through a well-rounded exploration of its properties and applications.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for bimatoprost ophthalmic solution.</p></list-item><list-item><p>Assess the different proposed mechanisms of action for ophthalmic bimatoprost solution to lower intraocular pressure and promote eyelash and hair growth.</p></list-item><list-item><p>Evaluate the administration doses and techniques of bimatoprost therapy.</p></list-item><list-item><p>Implement effective collaboration and communication strategies among interprofessional team members and patients to improve treatment efficacy and adherence to local medical therapy with bimatoprost.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=140421&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=140421">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-140421.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>
<bold>Glaucoma and Ocular Hypertension</bold>
</p>
        <p>Ophthalmic topical bimatoprost is a synthetic prostamide structurally related to prostaglandin F2 alpha (F<sub>2&#x003b1;</sub>). This drug received approval from the United States Food and Drug Administration (FDA) in 2001 as a treatment to lower intraocular pressure (IOP). Evidence&#x000a0;indicates that topical bimatoprost reduces&#x000a0;IOP in eyes with primary open-angle glaucoma (POAG) and ocular hypertension.<xref ref-type="bibr" rid="article-140421.r1">[1]</xref>&#x000a0;Growth of the eyelashes is a well-documented side effect of bimatoprost during the treatment of glaucoma.<xref ref-type="bibr" rid="article-140421.r2">[2]</xref><xref ref-type="bibr" rid="article-140421.r3">[3]</xref></p>
        <p>
<bold>Hypotrichosis</bold>
</p>
        <p>In 2008, the FDA-approved ophthalmic bimatoprost to treat hypotrichosis,&#x000a0;such as&#x000a0;for patients who are post-chemotherapy.<xref ref-type="bibr" rid="article-140421.r4">[4]</xref>&#x000a0;Bimatoprost ophthalmic solution is often purchased as an over-the-counter (OTC) ophthalmic applicator product for cosmetic purposes as&#x000a0;it can cause longer, thicker, and darker eyelashes.<xref ref-type="bibr" rid="article-140421.r5">[5]</xref>&#x000a0;Generic bimatoprost became available in 2015.&#x000a0;</p>
        <p>The ophthalmic bimatoprost is available in topical 0.01% and 0.03% concentrations. When used to lower IOP, a once-daily dosing of bimatoprost may be used alone or concomitantly with another drug, such as timolol.<xref ref-type="bibr" rid="article-140421.r6">[6]</xref>&#x000a0;In a 12-month comparison study in lowering IOP, bimatoprost 0.01% was comparable to bimatoprost 0.03%. However, the 0.01% formulation had less frequent and severe adverse ocular events, which became the primary concentration available in the United States.<xref ref-type="bibr" rid="article-140421.r7">[7]</xref> Preservative-free and generic formulations of bimatoprost are currently available worldwide.</p>
        <p>
<bold>Eyelash Growth</bold>
</p>
        <p>Once-daily bimatoprost ophthalmic solution of 0.03% applied to the upper eyelashes has been studied extensively to enhance eyelash growth with&#x000a0;favorable&#x000a0;safety profiles and tolerability.<xref ref-type="bibr" rid="article-140421.r2">[2]</xref><xref ref-type="bibr" rid="article-140421.r8">[8]</xref></p>
      </sec>
      <sec id="article-140421.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>
<bold>Chemistry</bold>
</p>
        <p>The molecular formula for bimatoprost is C<sub>25</sub>H<sub>37</sub>NO<sub>4</sub> (see <bold>Image</bold>.&#x000a0;Bimatoprost&#x000a0;Structure). The IUPAC chemical name is (<italic toggle="yes">Z</italic>)-7-[(1<italic toggle="yes">R</italic>,2<italic toggle="yes">R</italic>,3<italic toggle="yes">R</italic>,5<italic toggle="yes">S</italic>)-3,5-dihydroxy-2-[(<italic toggle="yes">E</italic>,3<italic toggle="yes">S</italic>)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-<italic toggle="yes">N</italic>-ethylhept-5-enamide. This drug is a synthetic prostamide analog that is structurally similar to prostaglandin (PG) F<sub>2&#x003b1;</sub>. Prostamides are fatty acid amides that differ from prostaglandins because they lack a negatively charged carboxylic acid and tend to be neutral.<xref ref-type="bibr" rid="article-140421.r9">[9]</xref> The pH ranges from 6.8 to 7.8. Bimatoprost has a molecular weight of 415.58 g/mol. The solution used in ophthalmology drops is sterile, colorless, isotonic, and clear, with an osmolarity of about 290 mOsm/kg.<xref ref-type="bibr" rid="article-140421.r10">[10]</xref> The multidose formulation has shown stability for at least 28 days when stored at 2 &#x000b0;C to 25 &#x000b0;C, with a shelf-life of about 2 years.<xref ref-type="bibr" rid="article-140421.r11">[11]</xref></p>
        <p>
<bold>Pharmacodynamics</bold>
</p>
        <p>Prostaglandins, which were initially thought to be derived from the prostate gland (hence the name), were first discovered in semen in the 1930s.<xref ref-type="bibr" rid="article-140421.r9">[9]</xref> Prostaglandins elicit effects via interaction with corresponding G-protein coupled receptors found throughout the body.<xref ref-type="bibr" rid="article-140421.r12">[12]</xref> Studies based on ocular extracts showed the presence of prostaglandins capable of contracting the iris. The effects of topically applied PG2&#x003b1; were first reported in human volunteers in 1985.<xref ref-type="bibr" rid="article-140421.r13">[13]</xref> PG receptors&#x000a0;exist in ciliary and corneal epithelium, iris stroma, ciliary muscle, choroid, trabecula meshwork, and retina.<xref ref-type="bibr" rid="article-140421.r14">[14]</xref> Of the&#x000a0;9 different types of prostaglandin receptors, bimatoprost has been shown to have an agonist activity and high affinity for PG receptors EP1, EP3, and FP.<xref ref-type="bibr" rid="article-140421.r15">[15]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Bimatoprost is a&#x000a0;synthetic&#x000a0;structural analog of prostaglandin&#x000a0;F<sub>2&#x003b1;</sub> and has been hypothesized to&#x000a0;exert its effects as an agonist through prostaglandin FP receptors.<xref ref-type="bibr" rid="article-140421.r16">[16]</xref><xref ref-type="bibr" rid="article-140421.r17">[17]</xref>&#x000a0;Because bimatoprost is&#x000a0;an amide rather than an ester, it is often labeled as a prostamide.<xref ref-type="bibr" rid="article-140421.r18">[18]</xref> When applied topically, penetration occurs through the cornea and sclera. The preferential target for this drug has been reported to be the ciliary body and cornea,&#x000a0;showing 10-fold higher concentrations in the ciliary body compared to aqueous humor.<xref ref-type="bibr" rid="article-140421.r19">[19]</xref><xref ref-type="bibr" rid="article-140421.r20">[20]</xref> Systemic absorption is minimal, reaching peak&#x000a0;plasma concentrations within 10 minutes and no longer detectable after 2 hours, with no signs of tissue accumulation.<xref ref-type="bibr" rid="article-140421.r21">[21]</xref> The elimination half-life of the drug administered intravenously is about 45 minutes, mainly through urine and about 25% via feces.<xref ref-type="bibr" rid="article-140421.r22">[22]</xref>&#x000a0;</p>
        <p>
<bold>Mechanism of Action in the Reduction of Intraocular Pressure&#x000a0;</bold>
</p>
        <p>It has been well demonstrated and validated that bimatoprost and several topical prostaglandin analogs sustainably and effectively reduce interaocular pressure (IOP) and are used as&#x000a0;a standard first-line treatment of POAG.<xref ref-type="bibr" rid="article-140421.r23">[23]</xref>&#x000a0;This is achieved primarily through enhancing aqueous&#x000a0;outflow through the uveoscleral&#x000a0;pathway.<xref ref-type="bibr" rid="article-140421.r24">[24]</xref>&#x000a0;Specifically, bimatoprost&#x000a0;increases&#x000a0;the level of remodeling enzymes like tissue inhibitors of metalloproteinases (TIMP) and matrix metalloproteinases (MMP) in the ciliary muscles and sclera, in addition to causing a widening of the spaces in connective tissue to enhance aqueous outflow.<xref ref-type="bibr" rid="article-140421.r25">[25]</xref>&#x000a0;These MMPs then induce the decomposition of collagen within the extracellular matrix, resulting in improved pressure-insensitive uveoscleral outflow.<xref ref-type="bibr" rid="article-140421.r26">[26]</xref> Ciliary muscle relaxation and contractile activity&#x000a0;induced by bimatoprost have also been shown to play a role in decreasing IOP.<xref ref-type="bibr" rid="article-140421.r27">[27]</xref><xref ref-type="bibr" rid="article-140421.r28">[28]</xref></p>
        <p>Several&#x000a0;studies have also&#x000a0;demonstrated that bimatoprost&#x000a0;might&#x000a0;have a bimodal mechanism and encourage trabecular and uveoscleral outflow.<xref ref-type="bibr" rid="article-140421.r24">[24]</xref>&#x000a0;Studies based on prostaglandins have shown that this class of drugs can also cause a relaxation of the trabecular meshwork (TM), thus enhancing conventional pressure-sensitive outflow mechanisms.<xref ref-type="bibr" rid="article-140421.r29">[29]</xref> Bimatoprost has not&#x000a0;demonstrated any effect on aqueous humor production to reduce IOP.<xref ref-type="bibr" rid="article-140421.r30">[30]</xref></p>
        <p>
<bold>Clinical Efficacy</bold>
</p>
        <p>It is shown that lowering IOP in patients with ocular hypertension and glaucoma may reduce the risk of disease progression.<xref ref-type="bibr" rid="article-140421.r7">[7]</xref> All forms of current treatment, including medical topical drops, laser treatments, and surgery, are all geared at lowering IOP to slow down irreversible glaucomatous progression.<xref ref-type="bibr" rid="article-140421.r31">[31]</xref> Numerous studies have confirmed that IOP reduction ranges from 28% to 31% with prostaglandins.<xref ref-type="bibr" rid="article-140421.r32">[32]</xref></p>
        <p>Compared to the other current forms of prostaglandin ocular drops, which include latanoprost, travoprost, and tafluprost, numerous studies have confirmed that bimatoprost has greater or similar efficacy in reducing IOP than others.<xref ref-type="bibr" rid="article-140421.r33">[33]</xref> Several randomized trials have shown that the switch from other prostaglandins to bimatoprost showed better IOP-reducing efficacy than travoprost, tafluprost, and latanoprost&#x000a0;with little switching back rates and a small statistically significant reduction in mean IOP after the switch.<xref ref-type="bibr" rid="article-140421.r34">[34]</xref><xref ref-type="bibr" rid="article-140421.r35">[35]</xref></p>
        <p>The effects in reducing IOP begin about 4 hours after the topical instillation of bimatoprost, which reaches maximum effects after 8 to 12 hours and lasts for 24 hours; it must be administered only once daily, preferably at night.<xref ref-type="bibr" rid="article-140421.r36">[36]</xref>&#x000a0;</p>
        <p>Bimatoprost (Lumigan) first became available in 2001 as a multidose 0.03% (0.3 mg/mL) ophthalmic solution with benzalkonium chloride (BAK). This prostaglandin reduces IOP and is considered one of the most efficient antiglaucomatous topical and first-line therapies compared to other monotherapy drop alternatives.<xref ref-type="bibr" rid="article-140421.r37">[37]</xref> Although bimatoprost 0.03% is very effective in reducing IOP, compliance rates tend to be less when compared to other prostaglandins due to the adverse effects&#x000a0;of conjunctival hyperemia, eyelash growth, periocular redness, and pigmentation, which tend to be higher with bimatoprost 0.03%.<xref ref-type="bibr" rid="article-140421.r38">[38]</xref><xref ref-type="bibr" rid="article-140421.r39">[39]</xref> Preservative-free formulations of 0.03% bimatoprost then became available to reduce the adverse effects of BAK on the ocular surface.<xref ref-type="bibr" rid="article-140421.r40">[40]</xref></p>
        <p>In 2010, Allergan&#x000a0;began selling Lumigan 0.01% (0.1 mg/mL) ophthalmic solution to the public. Numerous studies comparing the 2 different single and fixed formulations of bimatoprost, 0.03% and 0.01%, have reported similar efficacy in reducing IOP but less adverse effects for bimatoprost 0.01% in patients with glaucoma and ocular hypertension.<xref ref-type="bibr" rid="article-140421.r41">[41]</xref><xref ref-type="bibr" rid="article-140421.r42">[42]</xref> Preservative-free formulations of bimatoprost 0.01% and generics are currently available, which have shown similar efficacy in reducing IOP with a better tolerability profile when compared to other bimatoprost formulations.<xref ref-type="bibr" rid="article-140421.r43">[43]</xref></p>
        <p>The majority of the studies regarding bimatoprost have shown clinical efficiency and first-line therapy&#x000a0;in reducing IOP in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT).<xref ref-type="bibr" rid="article-140421.r44">[44]</xref><xref ref-type="bibr" rid="article-140421.r45">[45]</xref>&#x000a0;Numerous trials have included patients with different forms of glaucoma, like pseudoexfoliative, pigmentary,&#x000a0;chronic angle-closure,&#x000a0;etc.<xref ref-type="bibr" rid="article-140421.r42">[42]</xref><xref ref-type="bibr" rid="article-140421.r46">[46]</xref><xref ref-type="bibr" rid="article-140421.r47">[47]</xref></p>
        <p>
<bold>Safety and Tolerability</bold>
</p>
        <p>Treatment with bimatoprost once daily has a favorable safety profile and efficacy and is tolerated in most patients with glaucoma and ocular hypertension when compared with other prostaglandins.<xref ref-type="bibr" rid="article-140421.r48">[48]</xref> The adverse effects of conjunctival hyperemia, periocular pigmentation, and eyelash growth are slightly higher with the bimatoprost 0.03% formulation.<xref ref-type="bibr" rid="article-140421.r49">[49]</xref>&#x000a0;However, the 0.01% preservative-free formulation shows improvement in ocular side effects similar to other prostaglandins, corresponding to improved patient comfort and enhanced therapeutic compliance.<xref ref-type="bibr" rid="article-140421.r50">[50]</xref> &#x000a0;</p>
        <p>
<bold>Prevalence and Pharmacoeconomics</bold>
</p>
        <p>It has been estimated that more than 110 million people worldwide (older than 40 years old) will be affected by glaucoma in 2040.<xref ref-type="bibr" rid="article-140421.r51">[51]</xref> Annual costs for treating glaucoma in 2000 were reported to be more than $1 billion in the US and $200 million in Canada, with about 50% undiagnosed and not treated because of the asymptomatic nature of the disease.<xref ref-type="bibr" rid="article-140421.r52">[52]</xref> The annual health-related costs for glaucoma worldwide reported in 1999 ranged from $300 to $950 per patient, with 25% to 35% of the expenses for drug therapy.<xref ref-type="bibr" rid="article-140421.r52">[52]</xref></p>
        <p>The only identified modifiable risk factor to slow down or prevent glaucomatous progression and vision loss is the reduction in IOP, in which first-line therapy is by medical management.<xref ref-type="bibr" rid="article-140421.r53">[53]</xref> Analyses based on cost-effective treatments by US healthcare providers for POAG and OHT showed lower costs per treatment with bimatoprost compared to other therapeutic regimens.<xref ref-type="bibr" rid="article-140421.r54">[54]</xref> Studies conducted in Austria, the UK, Finland, France, Spain, Asia, Italy, and numerous other parts of the world have confirmed the efficacy and cost-related benefits related to the use of bimatoprost in patients with OHT and POAG.<xref ref-type="bibr" rid="article-140421.r52">[52]</xref> European studies reported that adding bimatoprost to first-line therapy with timolol was the most common form of treatment in managing patients with glaucoma and OHT.<xref ref-type="bibr" rid="article-140421.r55">[55]</xref></p>
        <p>
<bold>Enhancement of Hair and Eyelash Growth</bold>
</p>
        <p>The ability of bimatoprost to&#x000a0;promote the growth and thickening of eyelashes&#x000a0;was first noted during glaucoma clinical trials to investigate the potential to reduce IOP. Although the previously mentioned prostaglandin receptors are involved in regenerating the dermal papilla outer root sheath and throughout hair follicles, it remains unknown whether bimatoprost affects this pathway.<xref ref-type="bibr" rid="article-140421.r16">[16]</xref><xref ref-type="bibr" rid="article-140421.r56">[56]</xref> Murine models have shown that bimatoprost stimulates eyelash hair growth and increases the length.<xref ref-type="bibr" rid="article-140421.r57">[57]</xref> The drug promotes anagen phases of hair growth by arresting catagen phase entry.&#x000a0;Bimatoprost&#x000a0;increases the generated hair's thickness and bulb diameter; it does not generate new hair follicles.<xref ref-type="bibr" rid="article-140421.r58">[58]</xref> Bimatoprost also tends to darken the treated lashes.<xref ref-type="bibr" rid="article-140421.r59">[59]</xref></p>
        <p>A series of studies demonstrated that with a 2-week course of bimatoprost, a&#x000a0;more significant&#x000a0;proportion of follicles were in the hair cycle's anagen phase and a decreased portion in the&#x000a0;telogen phase, suggesting an increased transition from telogen to anagen. The study hypothesized that this increased proportion of follicles in the anagen phase allows for the observable enhanced growth of eyelashes with bimatoprost.<xref ref-type="bibr" rid="article-140421.r3">[3]</xref>&#x000a0;The FDA approved bimatoprost 0.03% solution for treating hypotrichosis of eyelashes in 2008 after the reported side effects of this drug in patients using it for glaucoma and OHT.<xref ref-type="bibr" rid="article-140421.r60">[60]</xref></p>
        <p>Bimatoprost has also been considered for hypotrichosis of the eyebrow. A large randomized study of 357 subjects with hypotrichosis of the eyebrow reported a statistically significant increase of at least one grade in Global Wyebrow Assessment in patients treated with bimatoprost 0.03% compared with vehicle.<xref ref-type="bibr" rid="article-140421.r61">[61]</xref></p>
        <p>Other uses for bimatoprost include treatment for dermatological diseases, including alopecia, hair loss or repigmentation,&#x000a0;vitiligo,&#x000a0;and localized leukoderma.<xref ref-type="bibr" rid="article-140421.r58">[58]</xref><xref ref-type="bibr" rid="article-140421.r62">[62]</xref><xref ref-type="bibr" rid="article-140421.r63">[63]</xref> Bimatoprost has shown a higher percentage of hair regrowth than other treatment regimes in patients with autoimmune-induced patchy alopecia areata.<xref ref-type="bibr" rid="article-140421.r64">[64]</xref><xref ref-type="bibr" rid="article-140421.r65">[65]</xref> Clinical trials have also&#x000a0;demonstrated efficacy, safety, and benefits in women and men with androgenetic alopecia.<xref ref-type="bibr" rid="article-140421.r66">[66]</xref></p>
      </sec>
      <sec id="article-140421.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Applying Bimatoprost Ophthalmic Solution for Glaucoma and Ocular Hypertension</bold>
</p>
        <p>Bimatoprost ophthalmic solution&#x000a0;0.01% or 0.03% may be used as eye drops applied directly to the ocular surface. The suggested dose of bimatoprost is&#x000a0;1 drop every evening. The patient should wait 5 minutes between administering bimatoprost and other ophthalmic drugs and artificial tears. With bimatoprost, the reduction of IOP has been shown to begin after 4 hours, peak after 12 hours, and maintain stability in the decrease in IOP for 24 hours.<xref ref-type="bibr" rid="article-140421.r67">[67]</xref>&#x000a0;Clinical trials of 1-year duration demonstrate that bimatoprost effectively lowers IOP long-term and is generally well tolerated.<xref ref-type="bibr" rid="article-140421.r68">[68]</xref> A tissue can remove excess therapy around the lids and periorbital region to decrease the adverse local effects.</p>
        <p>
<bold>Applying Bimatoprost Ophthalmic Solution for Hypotrichosis</bold>
</p>
        <p>Bimatoprost ophthalmic solution 0.03% is most commonly used and associated with increased growth and prominence of eyelashes with once-daily administration. The medication and included applicators are currently available commercially as a bottled solution. Before application, patients should remove contact lenses. Applying any solution directly to the eye is not recommended. Every evening, a drop of the solution is applied to the single-use-per-eye applicator and brushed against the&#x000a0;base of the upper&#x000a0;eyelid margin.&#x000a0;The applicator is to be used with only one eye to prevent contamination.</p>
        <p>Evidence&#x000a0;suggests that the solution should be applied for at least 16 weeks for maximum eyelash prominence.<xref ref-type="bibr" rid="article-140421.r2">[2]</xref>&#x000a0;Bimatoprost solution on the scalp is recommended to treat alopecia, which can be combined with other therapy types.<xref ref-type="bibr" rid="article-140421.r69">[69]</xref></p>
        <p>
<bold>Application of a New&#x000a0;Bimatoprost Implant for Open-angled Glaucoma</bold>
</p>
        <p>Although the topical ophthalmic solution of bimatoprost is highly effective for reducing IOP, there are also serious concerns about disease management due to&#x000a0;poor adherence by the patients.<xref ref-type="bibr" rid="article-140421.r70">[70]</xref>&#x000a0;Factors associated with decreased adherence to the recommended treatments include difficulty with eye drop administration, frequent dosing, adverse side effects, false&#x000a0;perception of the disease, and forgetfulness.<xref ref-type="bibr" rid="article-140421.r70">[70]</xref>&#x000a0;</p>
        <p>Intracameral drug delivery systems have been developed to circumvent these concerns.<xref ref-type="bibr" rid="article-140421.r71">[71]</xref> A bimatoprost sustained-release implant was designed and approved in the USA in 2020 for patients with ocular hypertension and open-angle glaucoma.<xref ref-type="bibr" rid="article-140421.r72">[72]</xref>&#x000a0;The intracameral implant is a single, sterile, rod-shaped solid polymer that consists of a 10 or 15 &#x003bc;g dose of bimatoprost lasting 4 to 6 months.<xref ref-type="bibr" rid="article-140421.r73">[73]</xref>&#x000a0;The drug is preloaded into a single-used applicator and then injected into the anterior chamber, allowing the implant to&#x000a0;deliver the prostaglandin analog directly to the iris-ciliary body.</p>
        <p>A recent phase 3 trial demonstrated that after&#x000a0;3 administrations of the implants at day 1, week 16, and week 32, most patients did not require additional treatment after 12 months and demonstrated noninferiority to topical ophthalmic solutions for OAG.<xref ref-type="bibr" rid="article-140421.r74">[74]</xref><xref ref-type="bibr" rid="article-140421.r45">[45]</xref>&#x000a0;Studies have shown that the 2020 FDA-approved intracameral sustained-release implant of bimatoprost (Durysta) provided advantages related to patient adherence, ocular surface and periorbital adverse effects, and IOP reduction in patients with glaucoma.<xref ref-type="bibr" rid="article-140421.r72">[72]</xref><xref ref-type="bibr" rid="article-140421.r75">[75]</xref> The main safety concern with these intracameral implants remains the gradual, irreversible loss of corneal endothelial cells, especially in repeat implants.<xref ref-type="bibr" rid="article-140421.r76">[76]</xref></p>
        <p>The bimatoprost ocular ring is another sustained release method of ocular drug delivery.<xref ref-type="bibr" rid="article-140421.r53">[53]</xref> A polypropylene and silicone ring ranging in diameter from 24 to 29 mm is impregnated with bimatoprost. The ring is positioned between the lower and upper fornices and provides continuous bimatoprost delivery for up to 6 months, with IOP comparable to daily bimatoprost topical drops.<xref ref-type="bibr" rid="article-140421.r77">[77]</xref></p>
        <p>The use of contact lenses with micelle-laden drugs is being studied as an alternative drug delivery system. However, research tends to be limited to animal models, and the risks related to long-term contact use remain an essential limitation.<xref ref-type="bibr" rid="article-140421.r78">[78]</xref>&#x000a0;Nonasponges with bimatoprost and injection of drug-laden microspheres have been reported in the literature; they remain preliminary and experimental in animal studies.<xref ref-type="bibr" rid="article-140421.r79">[79]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-140421.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Numerous trials have demonstrated the high level of safety and tolerance of bimatoprost when applied to the ocular surface or eyelids.<xref ref-type="bibr" rid="article-140421.r68">[68]</xref><xref ref-type="bibr" rid="article-140421.r80">[80]</xref></p>
        <p>The most common adverse events related to the local use of bimatoprost eye drops&#x000a0;include:</p>
        <list list-type="order">
          <list-item>
            <p>Conjunctival hyperemia (see <bold>Image</bold>. Adverse Affects) which peaks by day 15, then tends to decrease after several months (up to 45% of patients)</p>
          </list-item>
          <list-item>
            <p>Eyelash growth and darkening (see <bold>Image</bold>. Adverse Affects) (15% to 35% of patients)</p>
          </list-item>
          <list-item>
            <p>Eye pruritus and erythema (see <bold>Image</bold>. Adverse Affects) (about 10% of patients)</p>
          </list-item>
          <list-item>
            <p>Blepharitis</p>
          </list-item>
          <list-item>
            <p>Conjunctivitis</p>
          </list-item>
          <list-item>
            <p>Dry eye syndrome</p>
          </list-item>
          <list-item>
            <p>Burning irritation</p>
          </list-item>
          <list-item>
            <p>Pigmentation of eyelid margins and periocular regions&#x000a0;(see <bold>Image</bold>. Mild Adverse Affects)</p>
          </list-item>
          <list-item>
            <p>Iris pigmentation&#x000a0;(see <bold>Image</bold>. Adverse Affects)</p>
          </list-item>
          <list-item>
            <p>Visual disturbances</p>
          </list-item>
          <list-item>
            <p>Eye stinging and pain</p>
          </list-item>
          <list-item>
            <p>Foreign body sensations</p>
          </list-item>
          <list-item>
            <p>Tearing</p>
          </list-item>
          <list-item>
            <p>Photophobia</p>
          </list-item>
          <list-item>
            <p>Superficial punctate keratits</p>
          </list-item>
          <list-item>
            <p>Periorbital fat atrophy and deepening of upper eyelid sulcus&#x000a0;<xref ref-type="bibr" rid="article-140421.r25">[25]</xref></p>
          </list-item>
        </list>
        <p>Studies have highlighted&#x000a0;prostaglandin-associated periorbitopathy commonly seen in prolonged use of topical prostaglandin analogs, especially with bimatoprost.<xref ref-type="bibr" rid="article-140421.r81">[81]</xref> Periorbitopathy is typically seen clinically as periorbital fat atrophy, mild ptosis, and deepening of the upper lid sulcus (seen in 80% of patients using bimatoprost).<xref ref-type="bibr" rid="article-140421.r82">[82]</xref><xref ref-type="bibr" rid="article-140421.r83">[83]</xref> A review noted an underreported incidence of discomfort and prostaglandin-associated periorbitopathy, possibly due to the topic being dominated by industry-sponsored studies.<xref ref-type="bibr" rid="article-140421.r84">[84]</xref>&#x000a0;</p>
        <p>These adverse effects of periorbital fat atrophy with bimatoprost are being considered in treating thyroid eye disease (TED). This disorder is due to an inflammatory response that can cause soft tissue expansion within the orbit, leading to exophthalmos. Preliminary clinical studies have shown potential benefits for TED-induced exophthalmos in patients taking bimatoprost.<xref ref-type="bibr" rid="article-140421.r85">[85]</xref></p>
        <p>Several case reports have illustrated an association between&#x000a0;bimatoprost use and the reactivation of herpetic keratitis.<xref ref-type="bibr" rid="article-140421.r86">[86]</xref><xref ref-type="bibr" rid="article-140421.r87">[87]</xref> One significant but rare side effect is developing or exacerbating anterior non-granulomatous uveitis.<xref ref-type="bibr" rid="article-140421.r88">[88]</xref><xref ref-type="bibr" rid="article-140421.r89">[89]</xref> The incidence of drug-induced uveitis is very low and tends to manifest clinically as anterior iridocyclitis.<xref ref-type="bibr" rid="article-140421.r90">[90]</xref></p>
        <p>Bimatoprost applied as an eye drop has also been associated with the alteration of iris pigmentation. The change and darkening of the iris are caused by increased melanosomes within the melanocytes in the iris stroma, not an increase in the number of melanocytes.<xref ref-type="bibr" rid="article-140421.r91">[91]</xref> Brown and hazel-colored irises are more at risk of hyperpigmentation with bimatoprost, which can be irreversible.<xref ref-type="bibr" rid="article-140421.r91">[91]</xref> Darkening of the iris tends to occur within the first year of treatment and increases in time with continual use of the drug. &#x000a0;</p>
        <p>Multiple case reports have suggested various prostaglandin analogs, such as bimatoprost and latanoprost, can be associated with cystoid macular edema (CME) due to their pro-inflammatory effects.<xref ref-type="bibr" rid="article-140421.r18">[18]</xref> CME is a form of thickening of the macula characterized by intraretinal cystic fluid-filled spaces visible with optical coherence tomography (OCT). Prostaglandins, especially bimatoprost, are thought to induce blood-aqueous barrier disruption and thus favor the formation of CME after surgery or in patients with other forms of ocular inflammation.<xref ref-type="bibr" rid="article-140421.r92">[92]</xref> Studies have documented a potential association between using ophthalmic prostaglandin analogs and CME after cataract surgery in patients with glaucoma. This justifies the temporary suspension of bimatoprost and modification in glaucoma therapy in patients undergoing surgery and with ocular infections and inflammation.<xref ref-type="bibr" rid="article-140421.r93">[93]</xref> Carbonic anhydrase inhibitors have shown to be a valid alternative to bimatoprost during the early pre and postoperative periods or in patients with inflammation at risk of CME.<xref ref-type="bibr" rid="article-140421.r94">[94]</xref><xref ref-type="bibr" rid="article-140421.r95">[95]</xref></p>
        <p>Regarding the cosmetic use of bimatoprost, studies have shown that the safety profile for&#x000a0;dermal application of bimatoprost ophthalmic solution 0.03% is more favorable than that seen&#x000a0;with topical eye drop application.<xref ref-type="bibr" rid="article-140421.r58">[58]</xref> The difference in dose may explain the significant difference in the likelihood of adverse effects between the 2 methods of bimatoprost application. A single application of a bimatoprost 0.03% dermally results in only about 5% of the amount applied for treatment for glaucoma.<xref ref-type="bibr" rid="article-140421.r59">[59]</xref> The following adverse effects have been reported in fewer than 4% of patients following dermal application:<xref ref-type="bibr" rid="article-140421.r59">[59]</xref></p>
        <list list-type="order">
          <list-item>
            <p>Conjunctival hyperemia (most common&#x000a0;in 3.6% of patients)</p>
          </list-item>
          <list-item>
            <p>Eye pruritus</p>
          </list-item>
          <list-item>
            <p>Skin hyperpigmentation</p>
          </list-item>
          <list-item>
            <p>Ocular irritation</p>
          </list-item>
          <list-item>
            <p>Dry eye syndrome</p>
          </list-item>
          <list-item>
            <p>Eyelid erythema</p>
          </list-item>
        </list>
        <p>Studies&#x000a0;including "before-and-after" images of patients using bimatoprost have shown the potential risks of developing prostaglandin-associated periorbitopathy due to periorbital fat atrophy and deepening of the upper eyelid sulcus.<xref ref-type="bibr" rid="article-140421.r96">[96]</xref> Patients must know the possible adverse side effects of lash-lengthening serums with bimatoprost and other prostaglandins.</p>
      </sec>
      <sec id="article-140421.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Bimatoprost is contraindicated in patients with a medical history of&#x000a0;bimatoprost hypersensitivity or hypersensitivity to ingredients within the formulation. These include preservatives such as benzalkonium chloride.</p>
        <p>Bimatoprost may not be appropriate for some cases of closed-angle glaucoma and inflammatory or neovascular glaucoma. Contact lenses should be removed before the bimatoprost ophthalmic solution is applied. They can be reinserted after 15 minutes.&#x000a0;</p>
        <p>The safety and efficacy of bimatoprost ophthalmic 0.03% dermal application for hypotrichosis have not been studied in children, neonates, and infants younger than&#x000a0;5 years old. The application should only be considered if the potential benefits justify the potential calculated risks.&#x000a0;</p>
        <p>Bimatoprost is considered a category-C drug for pregnancy. Bimatoprost ophthalmic solution has not been adequately studied in pregnant women and pediatric patients; it should be avoided or used cautiously in these cases unless deemed necessary.<xref ref-type="bibr" rid="article-140421.r11">[11]</xref>&#x000a0;The presence or absence of the drug in breast milk has not been established, considering the short half-life; it should be avoided during nursing if possible.<xref ref-type="bibr" rid="article-140421.r97">[97]</xref> Pressure can be placed over the tear duct for about a minute, and removal of excess therapy with a tissue can be considered after applying ocular drops to decrease the amount of drug in the bloodstream.<xref ref-type="bibr" rid="article-140421.r98">[98]</xref> Intraocular application of bimatoprost ophthalmic solution for glaucoma is contraindicated in neonates, infants, and children due to concern for pigmentation changes after long-term use.&#x000a0;</p>
        <p>Bimatoprost ophthalmic drops should be used with caution in patients with macular edema, uveitis, ocular inflammation, aphakia, complicated pseudophakia, a history of herpes simplex virus keratitis, and ocular inflammatory conditions.<xref ref-type="bibr" rid="article-140421.r10">[10]</xref></p>
      </sec>
      <sec id="article-140421.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>To treat glaucoma and ocular hypertension, bimatoprost ophthalmic solution should be initially monitored with regular clinic visits every 2 to 4 weeks until the patient's individualized target&#x000a0;IOP is achieved. After reaching the IOP goal, the patient can be reassessed every&#x000a0;6 months or at the clinician's discretion. Additional parameters to monitor include ocular peri-ocular pigmentation changes.&#x000a0;</p>
        <p>When using bimatoprost ophthalmic solution 0.03% dermally for hypotrichosis, monitoring for potential side effects is advised. When bimatoprost is discontinued, eyelashes may return to their original pre-treatment length and thickness.</p>
      </sec>
      <sec id="article-140421.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Currently, no studies have been performed to evaluate bimatoprost overdose in humans. If an overdose were to occur, manufacturers recommend supportive symptomatic treatment.</p>
      </sec>
      <sec id="article-140421.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Bimatoprost is among the most effective first-line treatments for open-angle glaucoma and eyelash hypotrichosis. Several large, double-masked randomized control trials have shown bimatoprost&#x02019;s superior efficacy in lowering IOP in primary open-angle glaucoma and ocular hypertension.<xref ref-type="bibr" rid="article-140421.r6">[6]</xref><xref ref-type="bibr" rid="article-140421.r80">[80]</xref> The efficacy of treatment of conditions including hypotrichosis and different forms of alopecia has been demonstrated in the literature.<xref ref-type="bibr" rid="article-140421.r99">[99]</xref></p>
        <p>Successful treatment of glaucoma is highly dependent on interprofessional efforts to educate, communicate, and monitor for compliance with consistent eye drop use. Patients educated on the importance of the daily bimatoprost intervention were significantly more likely to report lower IOP values, which is&#x000a0;critically important to preserve vision.<xref ref-type="bibr" rid="article-140421.r100">[100]</xref> Evidence demonstrates that most patients are not bothered by bimatoprost&#x02019;s most common side effect of hyperemia, especially if a healthcare team member has explained the importance of IOP-lowering medications.</p>
        <p>Ultimately, collaboration and communication amongst an interprofessional team of ophthalmologists, ophthalmic technicians, nurses, and the patient will ensure the best care for the patient. A well-educated patient will, in turn, improve patient acceptance and compliance with the prescribed medication, resulting in optimized outcomes.</p>
      </sec>
      <sec id="article-140421.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=140421&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=140421">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/140421/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=140421">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-140421.s11">
        <fig id="article-140421.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Bimatoprost Structure. Two-dimensional&#x000a0;structure image. Compound summary for CID 5311027: Bimatoprost. PubChem Compound Database. https://pubchem.ncbi.nlm.nih.gov/compound/5311027.&#x000a0; Accessed&#x000a0;April&#x000a0;14, 2024.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Bimatoprostx1x" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-140421.s12">
        <fig id="article-140421.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Adverse Effects. Adverse effects with bimatoprost drops include eyelash growth, mild conjunctival hyperemia, periorbital pigmentation, and ocular dryness. Contributed by M Zeppieri, MD,&#x000a0;and P Brusini, MD.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Bimatoprost" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-140421.s13">
        <fig id="article-140421.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Mild Adverse Effects.&#x000a0;Mild adverse effects&#x000a0;with bimatoprost 0.03% drops include darker skin and redness around eyelids, irritated eyes, and thicker and longer eyelashes. Contributed by M Zeppieri, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Bimatoprost__0.03" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-140421.s14">
        <title>References</title>
        <ref id="article-140421.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lindsley</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rouse</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Wormald</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dickersin</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.</article-title>
            <source>Ophthalmology</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>123</volume>
            <issue>1</issue>
            <fpage>129</fpage>
            <page-range>129-40</page-range>
            <pub-id pub-id-type="pmid">26526633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-induced eyelash growth.</article-title>
            <source>Dermatol Surg</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>36</volume>
            <issue>9</issue>
            <fpage>1361</fpage>
            <page-range>1361-71</page-range>
            <pub-id pub-id-type="pmid">20384750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barr&#x000f3;n-Hern&#x000e1;ndez</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Tosti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia.</article-title>
            <source>Expert Opin Investig Drugs</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>515</fpage>
            <page-range>515-522</page-range>
            <pub-id pub-id-type="pmid">28264599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wirta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Baumann</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bruce</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ahluwalia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Weng</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Daniels</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Safety and Efficacy of Bimatoprost for Eyelash Growth in Postchemotherapy Subjects.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>11</fpage>
            <page-range>11-20</page-range>
            <pub-id pub-id-type="pmid">26060513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Enhanced eyelashes: prescription and over-the-counter options.</article-title>
            <source>Aesthetic Plast Surg</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>116</fpage>
            <page-range>116-21</page-range>
            <pub-id pub-id-type="pmid">20730536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moon</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of fixed-combination bimatoprost/timolol ophthalmic solution.</article-title>
            <source>Patient Prefer Adherence</source>
            <year>2017</year>
            <volume>11</volume>
            <fpage>1069</fpage>
            <page-range>1069-1070</page-range>
            <pub-id pub-id-type="pmid">29200831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mantravadi</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2017</year>
            <volume>11</volume>
            <fpage>1273</fpage>
            <page-range>1273-1280</page-range>
            <pub-id pub-id-type="pmid">28744094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wirta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pariser</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Yoelin</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Arase</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McMichael</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weng</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Demos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vandenburgh</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Bimatoprost 0.03% for the Treatment of Eyelash Hypotrichosis: A Pooled Safety Analysis of Six Randomized, Double-masked Clinical Trials.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>8</volume>
            <issue>7</issue>
            <fpage>17</fpage>
            <page-range>17-29</page-range>
            <pub-id pub-id-type="pmid">26203317</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Cornell</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Fliri</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Martos</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Pettit</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kharlamb</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Garst</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Landsverk</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Struble</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Stamer</surname>
                <given-names>WD</given-names>
              </name>
            </person-group>
            <article-title>Bimatoprost, prostamide activity, and conventional drainage.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>48</volume>
            <issue>9</issue>
            <fpage>4107</fpage>
            <page-range>4107-15</page-range>
            <pub-id pub-id-type="pmid">17724194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patil</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Vajaranant</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Edward</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Bimatoprost - a review.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>10</volume>
            <issue>16</issue>
            <fpage>2759</fpage>
            <page-range>2759-68</page-range>
            <pub-id pub-id-type="pmid">19874254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curran</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Orman</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Bimatoprost/timolol: a review of its use in glaucoma and ocular hypertension.</article-title>
            <source>Drugs Aging</source>
            <year>2009</year>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>169</fpage>
            <page-range>169-84</page-range>
            <pub-id pub-id-type="pmid">19220073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doucette</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Prostaglandins in the eye: Function, expression, and roles in glaucoma.</article-title>
            <source>Ophthalmic Genet</source>
            <year>2017</year>
            <season>Mar-Apr</season>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>108</fpage>
            <page-range>108-116</page-range>
            <pub-id pub-id-type="pmid">27070211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giuffr&#x000e8;</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The effects of prostaglandin F2 alpha in the human eye.</article-title>
            <source>Graefes Arch Clin Exp Ophthalmol</source>
            <year>1985</year>
            <volume>222</volume>
            <issue>3</issue>
            <fpage>139</fpage>
            <page-range>139-41</page-range>
            <pub-id pub-id-type="pmid">3856545</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Angeli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Supuran</surname>
                <given-names>CT</given-names>
              </name>
            </person-group>
            <article-title>Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018).</article-title>
            <source>Expert Opin Ther Pat</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>10</issue>
            <fpage>793</fpage>
            <page-range>793-803</page-range>
            <pub-id pub-id-type="pmid">31462124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharif</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Crider</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>SX</given-names>
              </name>
            </person-group>
            <article-title>Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells.</article-title>
            <source>J Ocul Pharmacol Ther</source>
            <year>2003</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>501</fpage>
            <page-range>501-15</page-range>
            <pub-id pub-id-type="pmid">14733708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woodward</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Krauss</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Prostamides (prostaglandin-ethanolamides) and their pharmacology.</article-title>
            <source>Br J Pharmacol</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>153</volume>
            <issue>3</issue>
            <fpage>410</fpage>
            <page-range>410-9</page-range>
            <pub-id pub-id-type="pmid">17721551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crowston</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Lindsey</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Medeiros</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Weinreb</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>46</volume>
            <issue>12</issue>
            <fpage>4571</fpage>
            <page-range>4571-7</page-range>
            <pub-id pub-id-type="pmid">16303950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agange</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mosaed</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Prostaglandin-induced cystoid macular edema following routine cataract extraction.</article-title>
            <source>J Ophthalmol</source>
            <year>2010</year>
            <volume>2010</volume>
            <fpage>690707</fpage>
            <pub-id pub-id-type="pmid">21076526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Camras</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Sharif</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Wax</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Stjernschantz</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Bimatoprost, the prodrug of a prostaglandin analogue.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>92</volume>
            <issue>6</issue>
            <fpage>862</fpage>
            <page-range>862-3; author reply 863-4</page-range>
            <pub-id pub-id-type="pmid">18523093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woodward</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Krauss</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Protzman</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Bogardus</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kedzie</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Krauss</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Gil</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Kharlamb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Babusis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Welty</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tang-Liu</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Cherukury</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Burk</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Garst</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024).</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>2003</year>
            <month>May</month>
            <volume>305</volume>
            <issue>2</issue>
            <fpage>772</fpage>
            <page-range>772-85</page-range>
            <pub-id pub-id-type="pmid">12606640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hellberg</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Ke</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Haggard</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Klimko</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Graff</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF2alpha by human and rabbit ocular tissue.</article-title>
            <source>J Ocul Pharmacol Ther</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>97</fpage>
            <page-range>97-103</page-range>
            <pub-id pub-id-type="pmid">12804054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cantor</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Hoop</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wudunn</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yung</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Catoira</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Valluri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cortes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Acheampong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2007</year>
            <month>May</month>
            <volume>91</volume>
            <issue>5</issue>
            <fpage>629</fpage>
            <page-range>629-32</page-range>
            <pub-id pub-id-type="pmid">17135335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prum</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Mansberger</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Moroi</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Gedde</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Herndon</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Primary Open-Angle Glaucoma Suspect Preferred Practice Pattern(&#x000ae;) Guidelines.</article-title>
            <source>Ophthalmology</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>123</volume>
            <issue>1</issue>
            <fpage>P112</fpage>
            <page-range>P112-51</page-range>
            <pub-id pub-id-type="pmid">26581560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christiansen</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Nau</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>McLaren</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma.</article-title>
            <source>Ophthalmology</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>111</volume>
            <issue>9</issue>
            <fpage>1658</fpage>
            <page-range>1658-62</page-range>
            <pub-id pub-id-type="pmid">15350319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Subbulakshmi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kavitha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Venkatesh</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Prostaglandin analogs in ophthalmology.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2023</year>
            <month>May</month>
            <volume>71</volume>
            <issue>5</issue>
            <fpage>1768</fpage>
            <page-range>1768-1776</page-range>
            <pub-id pub-id-type="pmid">37203029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Effects of Topical Prostaglandin Analog on Macular Thickness Following Cataract Surgery with Postoperative Topical Bromfenac Treatment.</article-title>
            <source>J Clin Med</source>
            <year>2020</year>
            <month>Sep</month>
            <day>07</day>
            <volume>9</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">32906606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Romano</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Lograno</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Evidence for the involvement of cannabinoid CB1 receptors in the bimatoprost-induced contractions on the human isolated ciliary muscle.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>48</volume>
            <issue>8</issue>
            <fpage>3677</fpage>
            <page-range>3677-82</page-range>
            <pub-id pub-id-type="pmid">17652738</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Toris</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Gabelt</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>53 Suppl1</volume>
            <issue>SUPPL1</issue>
            <fpage>S107</fpage>
            <page-range>S107-20</page-range>
            <pub-id pub-id-type="pmid">19038618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Stamer</surname>
                <given-names>WD</given-names>
              </name>
            </person-group>
            <article-title>Differential effects of prostaglandin E2-sensitive receptors on contractility of human ocular cells that regulate conventional outflow.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2013</year>
            <month>Jul</month>
            <day>16</day>
            <volume>54</volume>
            <issue>7</issue>
            <fpage>4782</fpage>
            <page-range>4782-90</page-range>
            <pub-id pub-id-type="pmid">23766471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Nau</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>O'Byrne</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Hodge</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Toris</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>McLaren</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study.</article-title>
            <source>Ophthalmology</source>
            <year>2008</year>
            <month>May</month>
            <volume>115</volume>
            <issue>5</issue>
            <fpage>790</fpage>
            <page-range>790-795.e4</page-range>
            <pub-id pub-id-type="pmid">18452763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stein</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Khawaja</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Weizer</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Glaucoma in Adults-Screening, Diagnosis, and Management: A Review.</article-title>
            <source>JAMA</source>
            <year>2021</year>
            <month>Jan</month>
            <day>12</day>
            <volume>325</volume>
            <issue>2</issue>
            <fpage>164</fpage>
            <page-range>164-174</page-range>
            <pub-id pub-id-type="pmid">33433580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Duan</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients: A meta-analysis.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>98</volume>
            <issue>30</issue>
            <fpage>e16597</fpage>
            <pub-id pub-id-type="pmid">31348303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yildirim</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sahin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gultekin</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma.</article-title>
            <source>J Glaucoma</source>
            <year>2008</year>
            <season>Jan-Feb</season>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <page-range>36-9</page-range>
            <pub-id pub-id-type="pmid">18303382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cai</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Duan</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients.</article-title>
            <source>J Ophthalmol</source>
            <year>2021</year>
            <volume>2021</volume>
            <fpage>5586719</fpage>
            <pub-id pub-id-type="pmid">34123413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Law</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Caprioli</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid Health Maintenance Organization.</article-title>
            <source>Ophthalmology</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>112</volume>
            <issue>12</issue>
            <fpage>2123</fpage>
            <page-range>2123-30</page-range>
            <pub-id pub-id-type="pmid">16225924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curran</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.</article-title>
            <source>Drugs Aging</source>
            <year>2009</year>
            <volume>26</volume>
            <issue>12</issue>
            <fpage>1049</fpage>
            <page-range>1049-71</page-range>
            <pub-id pub-id-type="pmid">19929032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deshpande</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Sonty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% - an observational switch study.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2017</year>
            <volume>11</volume>
            <fpage>1371</fpage>
            <page-range>1371-1376</page-range>
            <pub-id pub-id-type="pmid">28794615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petricca</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Celenza</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Costagliola</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tranfa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Iorio</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Cytotoxicity, Mitochondrial Functionality, and Redox Status of Human Conjunctival Cells after Short and Chronic Exposure to Preservative-Free Bimatoprost 0.03% and 0.01%: An In Vitro Comparative Study.</article-title>
            <source>Int J Mol Sci</source>
            <year>2022</year>
            <month>Nov</month>
            <day>15</day>
            <volume>23</volume>
            <issue>22</issue>
            <pub-id pub-id-type="pmid">36430590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Figus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nardi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Piaggi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sartini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guidi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Martini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lazzeri</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients.</article-title>
            <source>Eye (Lond)</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>422</fpage>
            <page-range>422-9</page-range>
            <pub-id pub-id-type="pmid">24434659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pillunat</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Eschstruth</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>H&#x000e4;semeyer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thelen</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Foja</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leaback</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pfennigsdorf</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2016</year>
            <volume>10</volume>
            <fpage>1759</fpage>
            <page-range>1759-65</page-range>
            <pub-id pub-id-type="pmid">27672307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mrukwa-Kominek</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Misiuk-Hojlo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Csutak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stalmans</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Garhofer</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A randomized clinical trial comparing three fixed combinations of bimatoprost with timolol in patients with open-angle glaucoma or ocular hypertension.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2023</year>
            <month>May</month>
            <volume>39</volume>
            <issue>5</issue>
            <fpage>775</fpage>
            <page-range>775-783</page-range>
            <pub-id pub-id-type="pmid">37013445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>TYB</given-names>
              </name>
            </person-group>
            <article-title>Retrospective Analysis of Switching Bimatoprost 0.01% to Bimatoprost 0.03% in Patients with Various Types of Glaucoma and Ocular Hypertension.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2022</year>
            <volume>16</volume>
            <fpage>2385</fpage>
            <page-range>2385-2390</page-range>
            <pub-id pub-id-type="pmid">35936971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Filippelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Campagna</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ciampa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fioretto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Giannini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marino</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>dell'Omo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Costagliola</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma.</article-title>
            <source>J Clin Med</source>
            <year>2022</year>
            <month>Jun</month>
            <day>19</day>
            <volume>11</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">35743588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gedde</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Vinod</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Muir</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Lind</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mansberger</surname>
                <given-names>SL</given-names>
              </name>
              <collab>American Academy of Ophthalmology Preferred Practice Pattern Glaucoma Panel</collab>
            </person-group>
            <article-title>Primary Open-Angle Glaucoma Preferred Practice Pattern&#x000ae;.</article-title>
            <source>Ophthalmology</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>128</volume>
            <issue>1</issue>
            <fpage>P71</fpage>
            <page-range>P71-P150</page-range>
            <pub-id pub-id-type="pmid">34933745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bacharach</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tatham</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Belalc&#x000e1;zar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thieme</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Goodkin</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Bejanian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wirta</surname>
                <given-names>DL</given-names>
              </name>
              <collab>ARTEMIS 2 Study Group</collab>
            </person-group>
            <article-title>Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2).</article-title>
            <source>Drugs</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>81</volume>
            <issue>17</issue>
            <fpage>2017</fpage>
            <page-range>2017-2033</page-range>
            <pub-id pub-id-type="pmid">34724172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Birt</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Buys</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>II</given-names>
              </name>
              <name>
                <surname>Trope</surname>
                <given-names>GE</given-names>
              </name>
              <collab>Toronto Area Glaucoma Society</collab>
            </person-group>
            <article-title>Prostaglandin efficacy and safety study undertaken by race (the PRESSURE study).</article-title>
            <source>J Glaucoma</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>19</volume>
            <issue>7</issue>
            <fpage>460</fpage>
            <page-range>460-7</page-range>
            <pub-id pub-id-type="pmid">20051890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Menon</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Goodkin</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Triple Fixed-Combination Bimatoprost/Brimonidine/Timolol in Glaucoma and Ocular Hypertension in India: A Multicenter, Open-Label, Phase 3 Study.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2022</year>
            <volume>16</volume>
            <fpage>3559</fpage>
            <page-range>3559-3569</page-range>
            <pub-id pub-id-type="pmid">36274674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lemmens</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rossetti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Oddone</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sunaric-M&#x000e9;gevand</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hommer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vandewalle</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Francesca Cordeiro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McNaught</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Montesano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stalmans</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Comparison of preserved bimatoprost 0.01% with preservative-free tafluprost: A randomised, investigator-masked, 3-month crossover, multicentre trial, SPORT II.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2021</year>
            <month>Apr</month>
            <day>05</day>
            <fpage>11206721211006573</fpage>
            <pub-id pub-id-type="pmid">33818170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bourne</surname>
                <given-names>RRA</given-names>
              </name>
              <name>
                <surname>Kaarniranta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lorenz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Traverso</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Vuorinen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ropo</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.</article-title>
            <source>BMJ Open</source>
            <year>2019</year>
            <month>Apr</month>
            <day>02</day>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>e024129</fpage>
            <pub-id pub-id-type="pmid">30944129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YI</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>YJ</given-names>
              </name>
            </person-group>
            <article-title>In Vivo Effects of Preservative-free and Preserved Prostaglandin Analogs: Mouse Ocular Surface Study.</article-title>
            <source>Korean J Ophthalmol</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>270</fpage>
            <page-range>270-9</page-range>
            <pub-id pub-id-type="pmid">26240512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tham</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Quigley</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Aung</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>CY</given-names>
              </name>
            </person-group>
            <article-title>Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis.</article-title>
            <source>Ophthalmology</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>121</volume>
            <issue>11</issue>
            <fpage>2081</fpage>
            <page-range>2081-90</page-range>
            <pub-id pub-id-type="pmid">24974815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plosker</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Keam</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension.</article-title>
            <source>Pharmacoeconomics</source>
            <year>2006</year>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>297</fpage>
            <page-range>297-314</page-range>
            <pub-id pub-id-type="pmid">16519552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chakrabarti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nazm</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Edward</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Newer advances in medical management of glaucoma.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>70</volume>
            <issue>6</issue>
            <fpage>1920</fpage>
            <page-range>1920-1930</page-range>
            <pub-id pub-id-type="pmid">35647957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alany</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Adherence, persistence and cost-consequence comparison of bimatoprost topical ocular formulations.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>9</issue>
            <fpage>1187</fpage>
            <page-range>1187-9</page-range>
            <pub-id pub-id-type="pmid">23829677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holmstrom</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Buchholz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Walt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wickstr&#x000f8;m</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aagren</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2006</year>
            <month>May</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>897</fpage>
            <page-range>897-905</page-range>
            <pub-id pub-id-type="pmid">16709311</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woodward</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Carling</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Cornell</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Fliri</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Martos</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Pettit</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products.</article-title>
            <source>Pharmacol Ther</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>120</volume>
            <issue>1</issue>
            <fpage>71</fpage>
            <page-range>71-80</page-range>
            <pub-id pub-id-type="pmid">18700152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tauchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Kellenberger</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Woodward</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Paus</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>L&#x000fc;tjen-Drecoll</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Characterization of an in vivo model for the study of eyelash biology and trichomegaly: mouse eyelash morphology, development, growth cycle, and anagen prolongation by bimatoprost.</article-title>
            <source>Br J Dermatol</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>162</volume>
            <issue>6</issue>
            <fpage>1186</fpage>
            <page-range>1186-97</page-range>
            <pub-id pub-id-type="pmid">20346040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2023</year>
            <volume>10</volume>
            <fpage>1130623</fpage>
            <pub-id pub-id-type="pmid">36999072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fagien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Whitcup</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ledon</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Somogyi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Weng</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Beddingfield</surname>
                <given-names>FC</given-names>
              </name>
            </person-group>
            <article-title>Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2012</year>
            <month>May</month>
            <volume>66</volume>
            <issue>5</issue>
            <fpage>801</fpage>
            <page-range>801-6</page-range>
            <pub-id pub-id-type="pmid">21899919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Law</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Bimatoprost in the treatment of eyelash hypotrichosis.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2010</year>
            <month>Apr</month>
            <day>26</day>
            <volume>4</volume>
            <fpage>349</fpage>
            <page-range>349-58</page-range>
            <pub-id pub-id-type="pmid">20463804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carruthers</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Beer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Carruthers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Draelos</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Pucci</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>VanDenburgh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weng</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Whitcup</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis.</article-title>
            <source>Dermatol Surg</source>
            <year>2016</year>
            <month>May</month>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>608</fpage>
            <page-range>608-17</page-range>
            <pub-id pub-id-type="pmid">27124878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yazdanian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mozafarpoor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goodarzi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review.</article-title>
            <source>Dermatol Ther</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>e14669</fpage>
            <pub-id pub-id-type="pmid">33314552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarsik</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>El-Amawy</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Uses of eye drops in dermatology, literature review.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>2758</fpage>
            <page-range>2758-2770</page-range>
            <pub-id pub-id-type="pmid">35652324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaher</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gawdat</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Hegazy</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Bimatoprost versus Mometasone Furoate in the Treatment of Scalp Alopecia Areata: A Pilot Study.</article-title>
            <source>Dermatology</source>
            <year>2015</year>
            <volume>230</volume>
            <issue>4</issue>
            <fpage>308</fpage>
            <page-range>308-13</page-range>
            <pub-id pub-id-type="pmid">25765294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fukumoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fukumoto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Magno</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Oka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nishigori</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Horita</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Treatments for alopecia areata: A systematic review and network meta-analysis.</article-title>
            <source>Dermatol Ther</source>
            <year>2021</year>
            <month>May</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>e14916</fpage>
            <pub-id pub-id-type="pmid">33631058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Bamimore</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Foley</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses, and an assessment of evidence quality.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>62</fpage>
            <page-range>62-72</page-range>
            <pub-id pub-id-type="pmid">32250713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Easthope</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.</article-title>
            <source>Drugs Aging</source>
            <year>2002</year>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>231</fpage>
            <page-range>231-48</page-range>
            <pub-id pub-id-type="pmid">12027782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Higginbotham</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Schuman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>VanDenburgh</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Whitcup</surname>
                <given-names>SM</given-names>
              </name>
              <collab>Bimatoprost Study Groups 1 and 2</collab>
            </person-group>
            <article-title>One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>120</volume>
            <issue>10</issue>
            <fpage>1286</fpage>
            <page-range>1286-93</page-range>
            <pub-id pub-id-type="pmid">12365906</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ali</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Hafiz</surname>
                <given-names>HSA</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Galal</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Combined microneedling with topical vitamin D3 or bimatoprost versus microneedling alone in the treatment of alopecia areata: A comparative randomized trial.</article-title>
            <source>J Cosmet Dermatol</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>1286</fpage>
            <page-range>1286-1296</page-range>
            <pub-id pub-id-type="pmid">36762396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Newman-Casey</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Robin</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Blachley</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Farris</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Heisler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Resnicow</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>PP</given-names>
              </name>
            </person-group>
            <article-title>The Most Common Barriers to Glaucoma Medication Adherence: A Cross-Sectional Survey.</article-title>
            <source>Ophthalmology</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>122</volume>
            <issue>7</issue>
            <fpage>1308</fpage>
            <page-range>1308-16</page-range>
            <pub-id pub-id-type="pmid">25912144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gautam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Karkhur</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sampath</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Intracameral Drug Delivery: A Review of Agents, Indications, and Outcomes.</article-title>
            <source>J Ocul Pharmacol Ther</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>102</fpage>
            <page-range>102-116</page-range>
            <pub-id pub-id-type="pmid">36757304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shirley</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Bimatoprost Implant: First Approval.</article-title>
            <source>Drugs Aging</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>37</volume>
            <issue>6</issue>
            <fpage>457</fpage>
            <page-range>457-462</page-range>
            <pub-id pub-id-type="pmid">32447639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seal</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bejanian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coote</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Attar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues.</article-title>
            <source>J Ocul Pharmacol Ther</source>
            <year>2019</year>
            <season>Jan/Feb</season>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>50</fpage>
            <page-range>50-57</page-range>
            <pub-id pub-id-type="pmid">30335560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Medeiros</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Walters</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Kolko</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coote</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bejanian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goodkin</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Weinreb</surname>
                <given-names>RN</given-names>
              </name>
              <collab>ARTEMIS 1 Study Group</collab>
            </person-group>
            <article-title>Phase 3, Randomized, 20-Month Study of&#x000a0;Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1).</article-title>
            <source>Ophthalmology</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>127</volume>
            <issue>12</issue>
            <fpage>1627</fpage>
            <page-range>1627-1641</page-range>
            <pub-id pub-id-type="pmid">32544560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Eaton</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Medical anti-glaucoma therapy: Beyond the drop.</article-title>
            <source>Vet Ophthalmol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>24 Suppl 1</volume>
            <fpage>2</fpage>
            <page-range>2-15</page-range>
            <pub-id pub-id-type="pmid">33164328</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sirinek</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Intracameral sustained release bimatoprost implants (Durysta).</article-title>
            <source>Semin Ophthalmol</source>
            <year>2022</year>
            <month>Apr</month>
            <day>03</day>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>385</fpage>
            <page-range>385-390</page-range>
            <pub-id pub-id-type="pmid">34586961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brandt</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>DuBiner</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Benza</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sall</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Semba</surname>
                <given-names>CP</given-names>
              </name>
              <collab>Collaborators</collab>
            </person-group>
            <article-title>Long-term Safety and Efficacy of a Sustained-Release Bimatoprost Ocular Ring.</article-title>
            <source>Ophthalmology</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>124</volume>
            <issue>10</issue>
            <fpage>1565</fpage>
            <page-range>1565-1566</page-range>
            <pub-id pub-id-type="pmid">28528010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ge</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Co-delivery of latanoprost and timolol from micelles-laden contact lenses for the treatment of glaucoma.</article-title>
            <source>J Control Release</source>
            <year>2019</year>
            <month>Jul</month>
            <day>10</day>
            <volume>305</volume>
            <fpage>18</fpage>
            <page-range>18-28</page-range>
            <pub-id pub-id-type="pmid">31103677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aref</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Sustained drug delivery for glaucoma: current data and future trends.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>169</fpage>
            <page-range>169-174</page-range>
            <pub-id pub-id-type="pmid">27764023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Safyan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Batoosingh</surname>
                <given-names>AL</given-names>
              </name>
              <collab>Bimatoprost Study Group</collab>
            </person-group>
            <article-title>Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>92</volume>
            <issue>10</issue>
            <fpage>1387</fpage>
            <page-range>1387-92</page-range>
            <pub-id pub-id-type="pmid">18621791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jbara</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Eiger-Moscovich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Didkovsky</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Keshet</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Avisar</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>In Vivo Effects of Prostaglandin Analogues Application by Topical Drops or Retrobulbar Injections on the Orbital Fat of a Rat Model.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>298</fpage>
            <page-range>298-303</page-range>
            <pub-id pub-id-type="pmid">35081015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kucukevcilioglu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bayer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Uysal</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Altinsoy</surname>
                <given-names>HI</given-names>
              </name>
            </person-group>
            <article-title>Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost.</article-title>
            <source>Clin Exp Ophthalmol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>126</fpage>
            <page-range>126-31</page-range>
            <pub-id pub-id-type="pmid">23844550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shrirao</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Khurana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mukherjee</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Prostaglandin-associated periorbitopathy.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>64</volume>
            <issue>6</issue>
            <fpage>459</fpage>
            <pub-id pub-id-type="pmid">27488155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steinsapir</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Steinsapir</surname>
                <given-names>SMG</given-names>
              </name>
            </person-group>
            <article-title>Revisiting the Safety of Prostaglandin Analog Eyelash Growth Products.</article-title>
            <source>Dermatol Surg</source>
            <year>2021</year>
            <month>May</month>
            <day>01</day>
            <volume>47</volume>
            <issue>5</issue>
            <fpage>658</fpage>
            <page-range>658-665</page-range>
            <pub-id pub-id-type="pmid">33625141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eiger-Moscovich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stiebel-Kalish</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yassur</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Barash</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gaton</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Avisar</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Prostaglandin analogue drops for the treatment of soft tissue expansion and exophthalmos in patients with inactive thyroid eye disease.</article-title>
            <source>Can J Ophthalmol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>54</volume>
            <issue>4</issue>
            <fpage>426</fpage>
            <page-range>426-430</page-range>
            <pub-id pub-id-type="pmid">31358139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kroll</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Schuman</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2002</year>
            <month>Mar</month>
            <volume>133</volume>
            <issue>3</issue>
            <fpage>401</fpage>
            <page-range>401-3</page-range>
            <pub-id pub-id-type="pmid">11860979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kothari</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Asher</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Kothari</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Recurrence of bilateral herpes simplex virus keratitis following bimatoprost use.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-8</page-range>
            <pub-id pub-id-type="pmid">16531673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woodward</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Haggerty</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Stinnett</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>ZY</given-names>
              </name>
            </person-group>
            <article-title>Bimatoprost 0.03% gel for cosmetic eyelash growth and enhancement.</article-title>
            <source>J Cosmet Dermatol</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>96</fpage>
            <page-range>96-102</page-range>
            <pub-id pub-id-type="pmid">20618554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Packer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Bilateral nongranulomatous anterior uveitis associated with bimatoprost.</article-title>
            <source>J Cataract Refract Surg</source>
            <year>2003</year>
            <month>Nov</month>
            <volume>29</volume>
            <issue>11</issue>
            <fpage>2242</fpage>
            <page-range>2242-3</page-range>
            <pub-id pub-id-type="pmid">14670442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cano Parra</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>D&#x000ed;az-Llopis</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Drug induced uveitis].</article-title>
            <source>Arch Soc Esp Oftalmol</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>80</volume>
            <issue>3</issue>
            <fpage>137</fpage>
            <page-range>137-49</page-range>
            <pub-id pub-id-type="pmid">15803424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kapur</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Osmanovic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Toyran</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Edward</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Bimatoprost-induced periocular skin hyperpigmentation: histopathological study.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>123</volume>
            <issue>11</issue>
            <fpage>1541</fpage>
            <page-range>1541-6</page-range>
            <pub-id pub-id-type="pmid">16286616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holl&#x000f3;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aung</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cantor</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Aihara</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cystoid macular edema related to cataract surgery and topical prostaglandin analogs: Mechanism, diagnosis, and management.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2020</year>
            <season>Sep-Oct</season>
            <volume>65</volume>
            <issue>5</issue>
            <fpage>496</fpage>
            <page-range>496-512</page-range>
            <pub-id pub-id-type="pmid">32092363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yeh</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Ramanathan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Latanoprost and clinically significant cystoid macular edema after uneventful phacoemulsification with intraocular lens implantation.</article-title>
            <source>J Cataract Refract Surg</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>10</issue>
            <fpage>1814</fpage>
            <page-range>1814-8</page-range>
            <pub-id pub-id-type="pmid">12388034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pepple</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Pakzad-Vaezi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Odell</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leveque</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Van Gelder</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>RESPONSE OF INFLAMMATORY CYSTOID MACULAR EDEMA TO TREATMENT USING ORAL ACETAZOLAMIDE.</article-title>
            <source>Retina</source>
            <year>2019</year>
            <month>May</month>
            <volume>39</volume>
            <issue>5</issue>
            <fpage>948</fpage>
            <page-range>948-955</page-range>
            <pub-id pub-id-type="pmid">29346240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Valk</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Webers</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Schouten</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Zeegers</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Hendrikse</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Prins</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials.</article-title>
            <source>Ophthalmology</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>112</volume>
            <issue>7</issue>
            <fpage>1177</fpage>
            <page-range>1177-85</page-range>
            <pub-id pub-id-type="pmid">15921747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jamison</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Okafor</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ullrich</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schiedler</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Malhotra</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Do Prostaglandin Analogue Lash Lengtheners Cause Eyelid Fat and Volume Loss?</article-title>
            <source>Aesthet Surg J</source>
            <year>2022</year>
            <month>Oct</month>
            <day>13</day>
            <volume>42</volume>
            <issue>11</issue>
            <fpage>1241</fpage>
            <page-range>1241-1249</page-range>
            <pub-id pub-id-type="pmid">35700523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Belkin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>DeOliveria</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ramulu</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Buys</surname>
                <given-names>YM</given-names>
              </name>
              <collab>American Glaucoma Society and the Canadian Glaucoma Society</collab>
            </person-group>
            <article-title>A Practical Guide to the Pregnant and Breastfeeding Patient with Glaucoma.</article-title>
            <source>Ophthalmol Glaucoma</source>
            <year>2020</year>
            <season>Mar-Apr</season>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>79</fpage>
            <page-range>79-89</page-range>
            <pub-id pub-id-type="pmid">32672600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blumen-Ohana</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sellem</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>[Pregnancy &#x00026; glaucoma: SFO-SFG recommendations].</article-title>
            <source>J Fr Ophtalmol</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-66</page-range>
            <pub-id pub-id-type="pmid">31813552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fagien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Walt</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Carruthers</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Wirta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weng</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Beddingfield</surname>
                <given-names>FC</given-names>
              </name>
            </person-group>
            <article-title>Patient-reported outcomes of bimatoprost for eyelash growth: results from a randomized, double-masked, vehicle-controlled, parallel-group study.</article-title>
            <source>Aesthet Surg J</source>
            <year>2013</year>
            <month>Aug</month>
            <day>01</day>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>789</fpage>
            <page-range>789-98</page-range>
            <pub-id pub-id-type="pmid">23873891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140421.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trattler</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Noecker</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Earl</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>A multicentre evaluation of the effect of patient education on acceptance of hyperaemia associated with bimatoprost therapy for glaucoma or ocular hypertension.</article-title>
            <source>Adv Ther</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>179</fpage>
            <page-range>179-89</page-range>
            <pub-id pub-id-type="pmid">18351298</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
